| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ | Director | Common Stock | 2,717,554 | $32,610,648 | $12 | 22 Jan 2024 | Indirect |
| Dianthus Therapeutics, Inc. /DE/ | Director | Pre-Funded Warrants (Right to Buy) | 1,833,333 | $21,998,163 | $12 | 22 Jan 2024 | Indirect |
| Dianthus Therapeutics, Inc. /DE/ | Director | Stock Option (Right to Buy) | 6,500 | 11 Sep 2023 | Indirect |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| DNTH | Dianthus Therapeutics, Inc. /DE/ | 22 Jan 2024 | 2 | $39,998,162 | 4 | Director | 24 Jan 2024, 18:55 |
| MGTA | Dianthus Therapeutics, Inc. /DE/ | 11 Sep 2023 | 1 | $0 | 4 | Director | 13 Sep 2023, 21:56 |
| MGTA | Dianthus Therapeutics, Inc. /DE/ | 11 Sep 2023 | 0 | $0 | 3 | Director | 13 Sep 2023, 21:31 |